Please select the option that best describes you:
Which PET imaging modality, if any, is preferred to work up possible nodal involvement or local recurrence in prostate cancer?
In situations where there is a significant risk of either local or nodal persistence/recurrence post prostatectomy with a rising PSA, or nodal involvement due to intermediate or high risk malignancy, of the new PET imaging modalities: the Blue Earth radiolabeled lysine analogue just approved by the FDA, or the radiolabeled Fab fragment to Prostate Cancer Membrane Antigen have you found helpful? How does either agent compare with C11 acetate or C11 choline, or multiparametric MRI to identify and localize the PSA signal?
Answer from: Radiation Oncologist at Academic Institution
In my view, better, more sensitive imaging will transform our management of prostate cancer. Soon, I believe, maybe very soon, we'll be able to detect small volume nodal metastases and small volume metastatic disease. How to manage patients with, say, a solitary, <1 cm lymph node seen on PET will...
Sign in or Register to read more